GLP-2 “TZ” 15mg

GLP-2 “TZ” — 15 mg

A 39-amino-acid, acylated dual incretin analog that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in in-vitro GPCR pharmacology. Lipidation via a long-chain diacid linker enhances albumin association and peptide persistence in cell-based systems. Supplied by Peptide Tech at ≥ 99% purity (HPLC/MS verified) for in-vitro, cellular, and biochemical research use only (RUO). Not for human or veterinary use.

Specifications

CAS Number	2023788-19-2
Chemical Name	Dual GIP/GLP-1 receptor agonist peptide
PubChem CID	156588324
Molecular Formula	C225H348N48O68 (free base)
Molecular Weight	≈ 4,813.5 g/mol (free base)
Sequence	39-aa dual incretin analog with Aib substitutions at positions 2 and 13; Lys20 acylated via γ-Glu–(AEEA)2–C20 fatty diacid; C-terminal amide; linear (no disulfides). Exact lot details: see COA.
Counter-ion	Acetate (typical; confirm on lot COA)
Physical Appearance	White to off-white lyophilized powder
Container	3 mL Type I glass vial, bromobutyl rubber stopper, aluminum flip-off seal (net content: 5 mg)
Purity	≥ 99% (verified by HPLC & MS; third-party tested)
Solubility	Soluble in sterile water; for concentrated stocks, pre-wet with ≤0.1–5% acetic acid and gently agitate. Consider 0.05–0.1% carrier protein to minimize adsorption; 0.22 µm filter-sterilize if required.

Molecular Structure (Reference)

Why Peptide Tech

• Same-Day Shipping
• USA Made
• 24/7 Support
• Price Match Guarantee
• Batch Tracking with QR Code Verification
• 3rd-Party USA Lab Testing — purity, quantity, endotoxin
• Cold-Chain Shipping — Always (no paid upgrade)
• Worldwide Shipping
• All Major Payments Accepted
• Text & Email Order Updates
• 2-Day FedEx/UPS Shipping Standard
• Cheapest Overnight Rates
• Largest Variety of Peptides & Bioregulators

Storage & Handling

• Lyophilized (unopened): Store at ≤ −20 °C, protected from light and moisture. For long-term archival, ≤ −80 °C is recommended.
• After reconstitution: Aliquot into sterile, low-binding tubes; store at ≤ −80 °C. Avoid repeated freeze–thaw cycles.
• Handling: Allow vial to reach room temperature before opening to minimize condensation. Use sterile technique and neutral-pH buffers; consider carrier protein to mitigate surface adsorption.
• Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

• GIPR/GLP-1R pharmacology: cAMP accumulation, β-arrestin recruitment, and receptor internalization in engineered cell systems.
• Biased signaling & pathway profiling: Quantify relative bias vs. selective GLP-1R or GIPR agonists.
• Ligand binding/occupancy: Competition and kinetic studies against mono-agonist comparators.
• Receptor cross-talk: Explore co-expressed GLP-1R/GIPR pathway integration and downstream transcriptional signatures.
• Formulation/stability: Assess adsorption, aggregation resistance, and excipient impacts under cell-culture conditions.

Citations (PubMed)

• Coskun, T., et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept.” Mol Metab, 2018. PMC
• Nauck, M. A., & Quast, D. R. “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist.” Diabetes Obes Metab, 2022. PMC
• Sun, B., et al. “Structural determinants of dual incretin receptor agonism by tirzepatide.” PNAS, 2022. PNAS
• Frias, J. P., et al. “Efficacy and safety of LY3298176, a dual GIP and GLP-1 receptor agonist.” Lancet, 2018. Link

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.